 we report on our first quarter 2022 financial results and provide an update on our preclinical programs in the hepatitis b and coronavirus space. 
 we also discuss the status of our 2 combination studies with 729 and 836. 
 finally, we provide an update on our efforts to develop a functional cure for chronic hepatitis b and a treatment for coronavirus outbreaks.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 